The association of NAD(P) H: Quinine oxidoreductase gene polymorphisms with pediatric acute lymphoblastic leukemia

Laboratory Medicine

Volumn 43, Issue 6, 2012, Pages 256-261

  Zaker, Farhad ^a   Safaei, Akram ^b   Nasiri, Nahid ^a   Abdollahzadeh, Maryam ^a   Pazhakh, Vahid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Acute lymphoblastic leukemia; NQO1; Polymorphism; RFLP

Indexed keywords

DIHYDROPTERIDINE REDUCTASE; QUININE OXIDOREDUCTASE [NAD(P)H]; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER RISK; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84869434239     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMTFQ7ZO8YEGAJ1H     Document Type: Article

References (37)

1. Pazhakh V, Razmkhah F, Zaker F, Farzaneh A, Parisa R. Methylenetetrahydrofolate reductase gene polymorphisms and risk of myeloid leukemia. LabMedicine. 2010;41(8):18-22.
2. Pui C-H, Schrappe M, Ribeiro RC, Neimayer CM. Childhood and adolescent lymphoid and myeloid leukemia. ASH Education Book. 2004:118-145.
3. Yamaguti G, Lourenço G, Silveira V, Tone LG, Lopes LP, Lima CP. Increased risk for acute lymphoblastic leukemia in children with cytochrome P450A1 (CYP1A1)- and NAD(P)H:quinone oxidoreductase 1 (NQO1)-inherited gene variants. Acta Haematol. 2010;124(3):182-184.
4. Gallegos-Arreola M, Batista-González CM, Delgado-Lamas JL, et al. Cytochrome P4501A1 polymorphism is associated with susceptibility to acute lymphoblastic leukemia in adult Mexican patients. Blood Cells Mol Dis. 2004;33(3):326-329.
5. Joseph T, Kusumakumary P, Chacko P, Abraham A, Pillai MR. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer. 2004;43(5):560-567.
6. Ernster L. DT-diaphorase: its structure, function, regulation, and role in antioxidant defence and cancer chemotherapy. In: Yagi K, ed. Pathophysiology of Lipid Peroxides and Related Free Radicals. Basel, Switzerland: S Karger AG; 1998:149.
7. Anwar A, Dehn D, Siegel D, Sachs L, et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem. 2003;278(12):10368-10373.
8. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA. 2002;99(5):3099-3104.
9. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004;382:115-144.
10. Metodiewa D, Jaiswal AK, Cenas N, Dickancaité E, Segura-Aguilar J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med. 1999;26(1-2):107-116.
11. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C-T polymorphism in the NAD(P)H:quinine oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803-807.
12. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomicina sensitivity. Cancer Res. 1992;52:797-802.
13. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE Review. Genet Med. 2005;7:463-478.
14. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852-854.
15. Gasdaska PY, Fisher H, Powis G. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. Cancer Res. 1995;55:2542-2547.
16. Pan S-S, Han Y, Farabaugh P, Xia H. Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T. Pharmacogenetics. 2002;12:479-488.
17. Malik E, Cohen SB, Dvorah C, Dann EJ, Rund D. The frequencies of NAD(P)H quinone oxidoreductase (NQO1) variant allele in Israeli ethnic groups and the relationship of NQO1*2 to adult acute myeloid leukemia in Israeli patients. Haematologica. 2006;91:956-959.
18. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993;7:349-360.
19. Clavel J, Bellec S, Rebouissou S, et al. Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev. 2005;14:531-540.
20. Wiemels JL, Pagnamenta A, Taylor GM, et al. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res. 1999:59;4095-4099.
21. Lanciotti M, Dufour C, Corral L, et al. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia. 2005;19:214-216.
22. Guha N, Chang JS, Chokkalingam A, et al. NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol. 2008;168:1221-1232.
23. Schulz WA, Krummeck A, Rösinger I, et al. Increased frequency of a null-allele for NAD (P) H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235-239.
24. Clairmont A, Sies H, Ramachandran S, et al. Association of NAD-(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis. 1999;20:1235-1240.
25. Eguchi-Ishimae M, Eguchi M, Ishii E, et al. The association of a distinctive allele of NAD(P)H:quinone oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. Haematologica. 2005;90(11):1511-1515.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1982.
27. Zaker F, Safaei A, Hashemi M, et al. The frequency and association of C609T and C465T polymorphisms of NAD (P) H: quinine oxidoreductase gene with adult acute myeloid leukemia. LabMedicine. 2011;42(11):18- 21.
28. Anwar A, Dehn D, Siegel D, et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem. 2003;278:10368-10373.
29. Kwang S, Gautam S, Abhinav J, et al. Genetic deletion of NAD(P) H:quinone oxidoreductase 1 abrogates activation of nuclear factor-jB, IjBa kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J Biol Chem. 2006;281:19798-19808.
30. Smith MT, Wang Y, Skibola CF, et al. Low NAD (P) H: quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood. 2002;100:4590-4593.
31. Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 2010;95(8):1405-1414.
32. Infante-Rivard C, Vermunt JK, Weinberg CR. Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia. Am J Epidemiol. 2007;165(11):1248-1254.
33. Sirma S, Agaoglu L, Yildiz I, et al. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia. Pediatr Blood Cancer. 2004;43(5):568-570.
34. Silveira Vda S, Canalle R, Scrideli CA, et al. Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen. 2010;51(1):48-56.
35. Krajinovic M, Sinnett H, Richer C, et al. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer. 2002;97(2):230-236.
36. Jeffrey N, Chang JS, Chokkalingam PA, et al. NQO1 Polymorphisms and De Novo Childhood Leukemia: A HuGE Review and Meta-Analysis. Am J Epidemiol. 2008;168:1221-1232.
37. Tuimala J, Szekely G, Gundy S, et al. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis. 2003;23:1003-1008